Sermorelin FDA Approval History: Geref, Discontinuation and Compounded Products
A regulatory history of sermorelin, including former Geref products, discontinuation and the status of compounded preparations.
Executive Summary
Sermorelin is a synthetic analogue of growth hormone-releasing hormone. The former Geref products are part of its U.S. regulatory history, but historical approval does not mean every sermorelin preparation available today is FDA approved or that new anti-aging and performance claims have been established.
What Geref Represented
Approval attaches to a specific drug application, dosage form, sponsor, population and indication—not to an ingredient in the abstract. The evidence supporting one application cannot automatically be transferred to a differently manufactured compounded preparation.
Approval History vs Current Marketing
FDA databases distinguish approval history from current marketing status. A discontinued product is not a currently marketed approved product. The relevant FDA record should be checked instead of inferring why a product left the market.
Where Compounded Products Fit
Compounded drugs are not FDA-approved products. FDA does not review them before marketing for the same demonstrations of safety, effectiveness and manufacturing quality required of an approved new drug. A clinic cannot use Geref's history to imply that its own compounded preparation is approved.
How to Assess a Claim
- Ask for the exact product and manufacturer, not only the ingredient.
- Check Drugs@FDA and historical labeling.
- Separate pediatric endocrine history from adult wellness claims.
- Confirm that cited evidence studies the same formulation and population.
Key Insight
Sermorelin's historical approval is relevant context, not a blanket endorsement of current compounded products or off-label outcome claims.